Vitrolife AB — Cyborg Score 7/10

Strategic Profile

Vitrolife maintains a global footprint with revenue generation across EMEA (Europe, Middle East, Africa), Americas, and Asia-Pacific regions, with EMEA representing the largest revenue contributor. The company's competitive advantage lies in its integrated portfolio of consumables, imaging systems, and laboratory equipment that enhance fertility treatment outcomes, positioning it as a specialized leader in the high-growth assisted reproduction market.

Cyborg Score Rationale

Vitrolife demonstrates solid fundamentals with stable revenue of approximately $350M, meaningful market capitalization of $1.39B, and a focused business model serving a structurally growing market with limited competition. The company benefits from recurring revenue through consumables and has expanded into genetic testing services, though execution risks and regulatory dependencies warrant careful monitoring.

Top Insights

• Market-leading position in assisted reproduction devices with ~1,116 employees enabling global manufacturing and R&D
• Diversified product portfolio spanning consumables (media, oils, pipettes), capital equipment (imaging systems), and services (genetic testing)
• Recession-resistant business model driven by fertility treatment demand, which is less sensitive to economic cycles than many healthcare segments
• Geographic diversification across three major regions mitigates regulatory and market concentration risks

Named Competitors

• Medical Device Solutions — Urologic and gynecological medical devices

Recent Developments

• (Feb 2026) Stock trading at $10.25 per share with market cap of $1.39B across 135M shares outstanding
• (Dec 2025) Trailing twelve-month revenue of $350M reflects stable organic growth and market position

Open the full interactive Vitrolife AB report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.